- Home
- OMC vs INCY Comparison
OMC vs INCY Comparison
Compare OMC & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMC | INCY |
|---|---|---|
| Founded | 1944 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.9B | 24.5B |
| IPO Year | 1994 | 1994 |
Fundamental Metrics
Financial Performance| Metric | OMC | INCY |
|---|---|---|
| Price | $88.01 | $121.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 28 |
| Target Price | $102.25 | ★ $131.50 |
| AVG Volume (30 Days) | ★ 2.9M | 1.7M |
| Earning Date | 10-22-2026 | 10-29-2026 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | N/A | ★ 4173.33 |
| EPS | ★ 5.77 | 0.50 |
| Revenue | ★ $17,271,900,000.00 | $3,394,635,000.00 |
| Revenue This Year | $50.82 | $17.74 |
| Revenue Next Year | N/A | $4.22 |
| P/E Ratio | ★ $15.02 | $243.91 |
| Revenue Growth | 10.09 | ★ 13.67 |
| 52 Week Low | $66.33 | $89.25 |
| 52 Week High | $89.57 | $132.60 |
Technical Indicators
Market Signals| Indicator | OMC | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 63.49 | 54.90 |
| Support Level | $73.53 | $120.79 |
| Resistance Level | $89.57 | $130.53 |
| Average True Range (ATR) | 2.36 | 4.17 |
| MACD | 0.47 | 0.60 |
| Stochastic Oscillator | 89.89 | 79.42 |
Price Performance
Historical ComparisonAbout OMC Omnicom Group Inc.
Omnicom is a holding company that owns several advertising agencies and related firms. It provides traditional and digital advertising services that include creative design, market research, data analytics, ad placement, and public relations. The firm operates globally, providing services in more than 70 countries; it generates more than 60% of its revenue in North America and 20% in Europe.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.